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Lung cancer is one of the four most prevalent cancers worldwide. Comprehensive patient 
care includes not only adherence to clinical guidelines to control and when possible cure 
the disease but also appropriate symptom control. Pain is one of the most prevalent 
symptoms in patients diagnosed with lung cancer; it can arise from local invasion of chest 
structures or metastatic disease invading bones, nerves, or other anatomical structures 
potentially painful. Pain can also be a consequence of therapeutic approaches like 
surgery, chemotherapy, or radiotherapy. Conventional medical management of cancer 
pain includes prescription of opioids and coadjuvants at doses sufficient to control the 
symptoms without causing severe drug effects. When an adequate pharmacological 
medical management fails to provide satisfactory analgesia or when it causes limiting 
side effects, interventional cancer pain techniques may be considered. Interventional 
pain management is devoted to the use of invasive techniques such as joint injections, 
nerve blocks and/or neurolysis, neuromodulation, and cement augmentation techniques 
to provide diagnosis and treatment of pain syndromes resistant to conventional medical 
management. Advantages of interventional approaches include better analgesic out-
comes without experiencing drug-related side effects and potential for opioid reduction 
thus avoiding central side effects. This review will describe various pain syndromes fre-
quently described in lung cancer patients and those interventional techniques potentially 
indicated for those cases.
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iNTRODUCTiON
Prevalence of Pain in Patients Diagnosed with Lung Cancer
Cancer and pain are clinical entities closely associated. Recent reviews suggest a prevalence of pain 
in cancer patients of 51% regardless of the type and stage. This prevalence increases with the type of 
tumor (head and neck, lung, and breast cancers are the ones with higher prevalence) and with the 
staging (advanced, metastatic, or terminal) reaching a 66% of cases (1).
Recent therapeutic advances have allowed increased survival rates potentially turning lung cancer 
into a chronic condition (2). Since pain is present in up to 39% of cases after curative intent, an 
increased survival could potentially impact this number of patients left with persistent symptoms 
despite being successfully treated.
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importance of Appropriate Symptom 
Control in Lung Cancer Patients
Undertreated cancer pain associates both physical and psycho-
logical consequences, causing suffering and reduced quality of 
life. Patients with unrelieved pain associate physical symptoms 
like insomnia, anorexia, profound fatigue, reduced cognition, and 
overall reduced vital capacity. Cancer patients presenting with 
unalleviated pain withdraw from social and familial interactions 
leading to isolation and psychological distress. Lastly, persistent 
pain can cause existential and spiritual suffering, which can limit 
the patient’s coping skills (3).
Basic Pharmacological Management to 
Relieve Cancer Pain
The World Health Organization (WHO) responded to an 
essential necessity to assess and treat cancer pain by designing in 
1986 the WHO Cancer Pain Relief guidelines [updated 10 years 
later (4)]. Adoption to the three step ladder approach leads to 
satisfactory cancer pain control in the majority of cases. However, 
in a significant proportion of patients, appropriate conventional 
medical management following the WHO guidelines do not war-
rant satisfactory analgesic control or may provoke limiting drug-
related side effects (5). For those cases, interventional cancer pain 
management may represent a valid option.
Definition of interventional Pain Medicine
Interventional pain management is a subspecialty of medicine 
devoted to the use of invasive techniques such as joint injections, 
nerve blocks and/or neurolysis, neuromodulation, and cement 
augmentation techniques to provide diagnosis and treatment 
of pain syndromes unresponsive to conventional medical 
management.
The basis of interventional pain practice lays on a profound 
knowledge of the anatomy and particularly the sensory innerva-
tion of different anatomical structures. When assessing a cancer 
pain case, aside from physiopathological considerations, the 
interventionalist may reflect about what is the anatomical struc-
ture that is hurting and which is the nerve supplying sensation to 
that structure.
As a principle, injections are avoided to be performed in the 
close vicinity of tumors for several reasons: (1) an increased risk 
of bleeding caused by abnormal tumor vascular neogenesis; (2) a 
risk of seeding cancer cells along the needle track, and (3) there 
is a risk of missing the target if the tumor has distorted the local 
anatomy. Routinely, nerve blocks are performed at levels where 
nerves are not damaged but are found proximal to the site of 
where the pain is coming from.
Several interventional cancer pain procedures have dem-
onstrated effectiveness in relieving drug-resistant cancer pain 
symptoms (6), yet the evidence is scant. This may explain why 
interventional procedures have not yet been adopted in clinical 
guidelines for the management of cancer pain and thus remain 
optional to teams with trained clinicians on board.
Scope of the Paper
This article aims to review the most common pain syndromes 
described in patients diagnosed with lung cancer. Treating 
physicians must be aware that conventional medical management 
is sufficient to achieve satisfactory pain management in most 
cases. Readers are encouraged to be familiar with comprehensive 
medical reviews on basic pharmacological analgesic approaches 
beyond the principles of the WHO (7, 8). The second part of this 
review lists the available interventional pain techniques indicated 
in cases of poor response to conventional medical management. 
A brief explanation of each technique with its peculiarities and 
scientific evidences, when available, is presented.
CLiNiCAL PAiN SYNDROMeS iN 
PATieNTS wiTH LUNG CANCeR
Pain in the Chest
Chest Wall Pain
Chest wall pain is a severe and disabling symptom. Over a half 
of lung cancer patients suffer from chest pain at diagnosis (9). 
Pain is usually ipsilateral to the tumor site and is described as 
dull, aching, persistent, and poorly localized. Chest pain can 
be particularly severe and better identified if secondary to a rib 
metastasis or when the primary tumor involves the chest wall or 
pleura. The majority of patients suffering from non-small cell 
lung cancer with chest wall invasion suffer from chest pain (10).
Costopleural Syndrome
It refers to the severe refractory chest pain, often observed in 
patients diagnosed with pleural mesothelioma. It is caused by 
tumor invasion of the pleural cavity and thoracic wall, and it is 
seen often in the early stages of the disease. This chest pain can 
be pleuritic in nature and also described as a dull and poorly 
localized pain arising and involving part of the hemi-thorax. It 
normally develops during the course of the disease thus worsen-
ing with disease progression and often becoming challenging 
to relieve with conventional drug management. Generally, the 
pain will present with mixed nociceptive and neuropathic pain 
features as the autonomic, intercostal, and occasionally brachial 
plexus nervous structures are involved (11).
Rib Bone Metastases
The primary symptom resulting from bone inflammation is pain, 
which may have a pleuritic component when the parietal pleura is 
involved. Since lung cancer metastases to bone are predominately 
lytic, periosteal inflammation and breach is the most common 
mechanism of pain from bone metastases (12). Additionally, 
metastases to the ribs often come associated with intercostal nerve 
damage and thus neuropathic pain. The pain usually is localized in 
a particular area and is often reported at night or on weight bear-
ing and with deep breathing. Pain is characteristically described 
as dull in character, constant in presentation, and progressively 
increasing in severity. At rest, the pain severity may be better 
controlled, thus patients may describe breakthrough pain related 
to postures and volitional or involuntary chest movements (13).
Pancoast Tumor
Pancoast tumor is defined as a malignant tumor arising from the 
lung apex, also referred to as superior sulcus tumor. The tumor 
usually affects adjacent structures such as ribs, blood vessels, and 
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nerves (typically the lower nerve roots of the brachial plexus). As a 
result, patients may present with severe pain, often of neuropathic 
characteristics radiating toward the ipsilateral upper extremity 
and accompanied with sympathetic symptoms (like the Horner 
syndrome) caused by invasion of the cervicothoracic sympathetic 
ganglion. These manifestations often appear months prior to the 
diagnosis of the underlining disease (14).
Malignant Brachial Plexopathy
Tumor infiltration of the brachial plexus is commonly seen 
among patients with lung cancer. It usually affects the lower 
elements of the nervous plexus but at times it may evolve into 
a panplexopathy. Presenting symptoms are typically pain at the 
shoulder and upper extremity associating with weakness, muscle 
atrophy, and sensory deficits. As the tumor expands and invades 
adjacent structures, the likelihood of reaching the epidural space 
becomes substantial (15).
Post-Thoracotomy Pain Syndrome
Between 25 and 60% of patients undergoing thoracic surgery 
develop persistent postoperative pain following the procedure 
(16). Post-thoracotomy pain syndrome (PTPS) is defined as pain 
along the surgical bed lasting more than 2 months post-thoracic 
resection surgery (17). It may occur after thoracotomy for malig-
nant or non-malignant lesions, it is usually restricted to one or 
more dermatomes. It is characterized by moderate to severe pain 
and typically described as numbness, tingling, burning, shooting, 
and sometimes itchy painful sensations. Sensory loss and allo-
dynia are usually present as well. The exact mechanism for the 
pathogenesis of PTPS remains unclear and is probably a combina-
tion of neuropathic and myofascial pain (MFP) (18). Genetics, 
age, gender, preoperative stress, and perioperative pain have been 
identified as predisposition factors for PTPS. The type and extent 
of surgery are also factors for the development of chronic pain 
particularly when there is trauma to the intercostal nerves.
Postherpetic Neuralgia
Cancer patients increasingly suffer from acute herpetic neuralgia 
(19). The Varicella Zoster virus, which remains dormant at the 
dorsal root ganglion after primary infection, is reactivated under 
certain circumstances like aging and immunosuppression, causing 
a skin rash usually restricted to a dermatomal distribution. Upon 
resolution of the skin lesions, patients develop the commonly 
known as postherpetic neuralgia. This pain, neuropathic in nature 
(20), is found most frequently affecting thoracic dermatomes. 
Pain management for both acute and chronic forms is challenging 
and relies mostly on pharmacology-based approaches. In severe 
cases, when conservative treatment fails to provide satisfactory 
relief of postherpetic neuralgic pain, interventional approaches 
could be attempted (21).
Bone Pain
Metastatic disease involving the musculoskeletal system is a 
common problem in oncology patients, occurring in up to 85% 
of patients diagnosed with breast, prostate, or lung cancer at the 
time of death (22). Bone metastases indicate a poor prognosis, 
with patients experiencing a median survival of 3 years or less; 
however, 5–40% of patients are alive at 5  years, dependent on 
tumor histology and disease burden (23). Metastatic bone disease 
leads to complications, such as pain, that can affect the patients’ 
quality of life. Bony metastases are frequent causes of pain 
among lung cancer patients as a result of pathological fractures, 
invasion of nearby pleural or visceral organs, involvement of 
neighbor nerve structures, spinal instability, and/or spinal cord 
compression. All of these complications are manifested as dif-
ficulty in ambulation or immobility and neurologic deficits (24). 
Pain symptoms arising from bone metastases present with mixed 
somatic and neuropathic features and are typically confined to a 
particular anatomical region. Pain often appears during the night 
and is exacerbated by weight bearing, posture change, or move-
ment, thus with a strong dynamic component. Pain starts over 
weeks or months with progressive worsening becoming more 
severe and continuous at rest or with exacerbation triggered by 
dynamic changes (7). When baseline pain is well controlled but 
the patient experiences sudden and short lasting crisis of severe 
pain (also known as breakthrough pain), the case becomes more 
challenging since the crisis can be unpredictable and the available 
pharmacological options may be unsatisfactory.
Although thought to be the optimal management, surgery 
often cannot be offered because of underlying medical conditions, 
poor functional status, poor bone quality, or presence of multiple 
bone metastases (25). Currently, the gold standard symptomatic 
treatment of focal bone pain caused by metastatic disease is exter-
nal beam radiation therapy. After radiation therapy most patients 
present with partial or complete pain relief; however, this relief is 
not achieved immediately but experienced after a considerable 
amount of time. In over 50% of patients, the pain relief is found 
temporary, and in 20–30% of cases the pain is not relieved (26, 
27). Patients who underwent radiation therapy presenting with 
localized recurrent pain in the irradiated region are not usually 
candidates to receive more radiation because the potential toxic 
impact on non-cancer tissues.
Unfortunately, standard chemotherapy is often ineffective to 
treat metastatic-related pain. Bisphosphonates and denosumab 
are agents with proven benefits in decreasing severity of bone-
related incidents in patients with metastatic bone disease. They 
may alleviate cancer-induced bone pain, yet there is insufficient 
evidence to recommend these therapies solely for pain relief 
purposes (28).
Myofascial Pain
In approximately 10% of cancer patients, pain is unrelated directly 
to the disease or treatment and is most often originated in muscles 
and connective tissues (29). MFP is started to be recognized as 
one of the most important causes of pain in cancer patients during 
treatment, at terminal stages, or after curative therapy (30). MFP 
is a syndrome characterized by regional chronic pain associating 
multiple myofascial trigger points and fascial constrictions. It can 
appear in any body part and characteristically features focal point 
tenderness, reproduction of pain and hardening of the muscle 
upon trigger point palpation, pseudo-weakness of the involved 
muscle, referred pain, and restricted range of motion (31). The 
treatment for MFP includes physical therapies like myofascial 
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trigger point needling and injections, myofascial release, and 
stretching exercises (32).
Pain Related to Diagnostic Procedures 
and Cancer Treatment
Certain diagnostic test and treatments can cause or aggravate 
pain because they require the patient to maintain an immobile 
posture like imaging test or radiotherapy (RT). Others cause pain 
due to their invasiveness such as transthoracic needle biopsy or 
thoracocentesis (33). These acute pain episodes are described 
as transient exacerbations of pain typically well managed with 
conventional analgesic medications. Chemotherapy and RT are 
treatments frequently associated with deleterious and persistent 
painful syndromes that are not easily managed.
Chemotherapy-induced painful neuropathy is one of the most 
common and better studied pain syndromes consequences of 
cancer therapy. Most of chemotherapy-induced pains are self-
limited and can be managed pharmacologically and/or with dose 
adjustments of the chemotherapeutic regimen. Probably, the better 
described chronic pain syndrome consequence of cancer treat-
ment is chemotherapy-induced peripheral neuropathic pain (34).
Cancer patients can potentially suffer from RT-related pain 
both immediately after the treatment and as a late complication. 
During the acute phase, RT causes pain due to skin or mucosa 
inflammation or due to the procedure itself. Patients subject to 
RT for bone metastasis commonly suffer from pain flare-ups in 
radiated areas (35) and are treated usually with breakthrough 
analgesics and steroids. At later stages, RT-related pain can be 
caused by a variety of mechanisms including soft-tissue fibrosis 
and sclerosis and muscle weakness, such as thoracic pain, shoul-
der pain, and cervical dystonia (36). Thoracic cancer patients 
receiving greater dosages may require opioids to treat brachial 
plexopathy or chest wall pain following radiation (37, 38).
iNTeRveNTiONAL PROCeDUReS
General Principles of interventional Pain 
Procedures in Cancer Patients
An interventional pain procedure is typically indicated when (a) 
the patient has not achieved satisfactory analgesic control despite 
optimal conventional medical management as suggested by the 
WHO guidelines or (b) when adequate pain control comes asso-
ciated with intolerable side effects (39). Additional indications 
may include (c) favoring analgesic control with opioid sparing 
techniques or (d) analgesia in patients that are poor candidates 
to opioid analgesia.
The key to a successful partnership between treating oncolo-
gists and interventional pain physicians is communication to 
sharing the cases, reviewing indications and contraindications, 
appraising the available scientific evidences, and updating the 
team about the patient’s status and goals of treatment, in sum-
mary creating a clinical pathway for these patients.
Overall, interventional pain procedures should be offered to 
patients before they are too frail to undergo the procedure, thus 
they should not be considered an option in isolation but rather 
a part of an analgesic strategy. Patients should be able to consent 
and they should, along with their caregivers and the treating 
team, understand the procedure, the expected benefits and side 
effects, and potential complications (40).
A bidirectional communication between teams allows for ear-
lier identification of candidates, thus preventing drug escalation 
and challenging cases. Additionally, the team must be updated 
on those fluctuations in the patient’s status that may potentially 
change the indication (risk of bleeding, infection, respiratory 
insufficiency). Following a successful procedure, the treating team 
must be vigilant for potential changes in analgesic requirements; 
ideally, opioids must be decreased to prevent central toxicity.
Peripheral Nerve injections
When cancer pain is experienced in the vicinity of an identified 
peripheral nerve, a temporary interruption of the pain transmis-
sion can be an effective method to control neuropathic pain. 
The term “nerve block” describes any procedure that utilizes a 
needle to deliver a local anesthetic or an ablative agent (phenol, 
alcohol, glycerin, etc.) for analgesic purposes. A block can have 
both diagnostic and therapeutic values. In order to identify the 
anatomical area and/or the afferent pathway involved in originat-
ing/conveying the pain sensation, a diagnostic nerve block may 
be effective. A prognostic block allows the decision to indicate a 
more complex and permanent procedure usually with neurolytic 
purposes. Diagnostic and prognostic blocks consist in injecting a 
small volume of a local anesthetic agent onto a nerve. The dura-
tion of the effect is usually short, depending on the potency of the 
local anesthetic agent injected. Patients are considered respond-
ers when most of their pain is significantly relieved during the 
following hours after the procedure. Neurolysis implies the focal 
destruction of nervous tissue as by the use of chemicals or thermal 
methods to disrupt nerve transmission. The classical targets for 
nerve blocks or neurolysis are sympathetic nerves or nerves with 
predominant sensory component. It is very important to always 
preserve motor and sphincter functions and when not possible, 
balance potential benefits against side effects before performing 
a neurolysis (40).
Among lung cancer pain patients, the most frequently targeted 
nerve structures are obviously located inside the thorax. As a gen-
eral principle, the interruption of nociception must be attempted 
at a proximal site to the pain generator (41). Patients with thoracic 
chest wall pain may benefit from procedures targeting (from 
distal to proximal) the intercostal nerve, the posterior root of the 
thoracic radicular nerve, and the paravertebral space.
Intercostal Nerve Blocks and Neurolysis
It consists in injecting the neural structure located underneath 
each rib. This is a simple procedure that can be performed at 
the patient’s bed site not requiring advanced imaging guidance 
systems. Because the main complication is the pleural puncture 
and subsequent pneumothorax, it is suggested direct needle 
placement with ultrasonography. The injection of an intercostal 
nerve provides loss of sensation distal to the point of injection 
following the trajectory of the nerve toward the anterior chest 
wall. The largest series reporting intercostal nerve procedures for 
chest pain management include 25 patients with metastatic rib 
lesion undergoing intercostal blocks. In this study, 80% of the 
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patients noted optimal local pain control and 56% experienced 
reduction in analgesic use after the procedure (42).
When a temporary intercostal nerve block provides adequate 
analgesia but limited to a short period of time, it may be reason-
able to repeat the block adding a coadjuvant (43) or opting for 
a more permanent relief by damaging the nerve with a chemi-
cal neurolysis with phenol (44), a thermal neurolysis with heat 
using radio-frequency (RF) (45, 46) or freezing the nerve with 
cryoneurolysis (47).
Thoracic Nerve Root and Paravertebral Procedures
This consists of injecting the thoracic nerve roots at their exit 
from the spinal canal. These nerve roots can be injected individu-
ally (selective thoracic nerve block/neurolysis) or several at the 
same time by placing a needle at the thoracic paravertebral space. 
The selective nerve root block technique has been suggested as a 
proximal alternative site of injection in cases of post-thoracotomy 
pain (48). Authors described the use of pulsed RF, which deliv-
ers electricity to the dorsal root ganglion without causing nerve 
tissue damage. Results favored this technique over treatment 
of intercostal nerves and over conventional pharmacological 
management.
The injection of neurolytic agents into the thoracic paraver-
tebral space presents advantages since one single injection may 
reach several thoracic nerve roots, thus involving a larger ana-
tomical area. Neurolytic injection of the thoracic paravertebral 
space has been also described in cases of lung cancer with chest 
wall pain. In a small case series, injection of phenol in the vicin-
ity of thoracic nerve roots provided satisfactory yet short lasting 
chest pain relief (49).
Brachial Plexus Procedures
Pain to the upper limb caused by lung cancer has been reported 
in cases of Pancoast tumors. The involvement of the sympathetic 
chain and the brachial plexus may cause neuropathic symptoms 
radiated toward the arm and the hand. Anesthetic techniques tar-
geting the brachial plexus may include intermittent or continuous 
injection of local anesthetics (50) and neurolysis with phenol (51).
Spinal injections
Drugs injected into the spinal canal act through direct interaction 
with spine receptors thus achieving more potent analgesic effects 
with minimal doses. Additionally, the effect may be restricted 
to few dermatomes, hence sparing the possible side effects to 
a targeted anatomical area. The two modalities of intraspinal 
procedures available to manage drug-resistant pain secondary 
to lung cancer are continuous spinal drug delivery or spinal 
neurolytic procedures.
Continuous Drug Delivery
The basics of neuraxial analgesia consist of a catheter inserted 
into the spinal canal and a pump to administering medication 
in a continuous fashion. Opioids alone or combined with local 
anesthetics and other substances, such as clonidine or ziconotide, 
can be administered via epidural or intrathecal route to achieve 
neuraxial analgesia. Neuraxial analgesia allows the use of lower 
dosages of opioids, hence minimizing systemic side effects. As 
an example of the potency of intraspinal opioids: 300  mg PO 
morphine/day =  100  mg IV morphine/day =  10  mg epidural 
morphine/day = 1 mg intrathecal morphine/day (52).
Patient selection for spinal drug delivery includes choice of 
the anatomical space to deliver the drug (epidural vs. intrathecal) 
and choice of the administration mode (external infusion with 
syringe driver/pump vs. implanted reservoir with automated 
pump). The selection of the system is determined by factors like 
survival expectancy, body habit, patient admitted or ambulatory, 
financial resources, and/or expertise of the treating team (53).
For those patients with reduced life expectancy (<3 months), 
the neuraxial method of choice remains the epidural route. The 
main advantages of epidural opioid delivery are reduced risk of 
pharmacological complications, theoretical dermatomal analge-
sia achieved when combined with local anesthetics, decreased 
risk of post-dural puncture headache, and potentially, more 
familiarity within other specialties. On the other side, continuous 
epidural analgesia requires infusion of larger volumes of medica-
tion and a higher risk of catheter-related complications since it is 
not normally anchored or internally implanted (54).
Intrathecal drug delivery has been extensively described in 
the literature for the management of drug-resistant cancer pain 
syndromes. Available guidelines can be found to identifying 
the best candidates for this analgesic therapy (55). Advantages 
of intrathecal systems include better pain control with lower 
dosages, lower risk of catheter-related complications, and totally 
implanted systems thus, reduced rate of infections (56). Direct 
comparison of intrathecal drug delivery vs. conventional medical 
management favors the experimental arm in quality of analgesia, 
profile of side effects, and survival rates (57).
Intraspinal Neurolysis
Pain relief in terminal cancer cases achieved by means of injection 
of a neurolytic agent has been extensively reported (58). The key 
for a successful neurolytic procedure is balancing the expected 
analgesia and the potential nerve deficits associated.
These neurolytic procedures seem to be restricted to the latest 
option in the interventional cancer pain armamentarium (59) 
because they carry inevitable nerve deficits and because intraspi-
nal drug delivery systems have become more available.
For lung cancer pain patients, the options include epidural (60) 
or intrathecal (58) injections of neurolytic agents such as alcohol 
or phenol. Because these neurolytic approaches are usually left 
as a last resort in the management of severe and drug-resistant 
cancer pain in terminally ill patients, the available evidences 
are only restricted to case series. From those evidences, it can 
be inferred that intraspinal neurolysis is a complex analgesic 
technique providing satisfactory analgesia but carrying a high 
potential for neurological deficits that must be weighted before 
performing the technique.
electrical Neuromodulation Techniques
Electrical neuromodulation is a technique by which an electrode 
that is placed next to a nervous structure stimulates selective small 
nerve fibers, which in turn inhibit nociception through complex 
physiological mechanism. Neurostimulation can be achieved 
via placement of electrodes under the skin (subcutaneous/field 
6Hochberg et al. Interventional Cancer Pain Management
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 17
stimulation), close to peripheral nerves or to spinal nerve roots 
(peripheral nerve/DRG stimulation), inside the epidural space 
close to the ascending dorsal columns [spinal cord stimulation 
(SCS)], or inside the brain (deep brain stimulation). The efficacy, 
safety, and cost-effectiveness of neurostimulation techniques in 
the management of chronic pain of non-cancer origin have been 
sufficiently demonstrated in the last decade (61).
Conversely, because of its cost, the indication for neuro-
stimulation in cancer pain patients is usually restricted to those 
cases when cancer has been successfully cured but patients are 
left with painful permanent consequences. There are no rand-
omized trials addressing the benefits of SCS for cancer-related 
pain (62). Indications for SCS included chest wall pain (63) or 
chemotherapy-induced neuropathy (64), for example.
Neurosurgical Procedures
Historically, destructive procedures for cancer pain were the main 
line of treatment therapy in the previous two centuries; however, 
the availability of opioids, coadjuvants, and newer anesthetic 
techniques has essentially replaced such procedures (65). The 
indication of these techniques is restricted to anecdotal reports 
nowadays.
Percutaneous Cervical Cordotomy
This procedure consists of creating a lesion to the lateral spi-
nothalamic tract. The purpose is to disrupt the pain transmission 
carried from the contralateral side, as the spinothalamic tract car-
ries pain, temperature, and some tactile information. The lesion 
is usually done percutaneously through the C1–C2 level (66). 
This procedure has been shown to be most effective in patients 
with confined unilateral nociceptive pain, such as in the case of 
mesothelioma (67) or other malignant invasions of the chest wall.
The complications involved are substantial with 3% mortal-
ity, up to 11% motor weakness, and others such as respiratory, 
postcordotomy hypotension, bladder dysfunction, sexual dys-
function, and dysethesia (68).
Intracerebroventricular Opioid Delivery
Intracerebroventricular opioids are useful for intractable pain 
when other simpler techniques have failed. It consists of deliver-
ing opioids via a ventricular catheter attached to a subcutaneous 
storage (69).
Cingulotomy
This procedure refers to lesioning of the anterior cingulate cortex, 
which is a component of the limbic system that affects a wide 
array of functions involving behavior, emotions, and others. It 
is indicated in cancer pain patients with significant emotional 
distress. A case report from 2014 described bilateral anterior cin-
gulotomy effectively relieved both pain and dyspnea for a patient 
with malignant mesothelioma (70).
Procedures for Localized Painful Bone 
Metastases
Cement Augmentation Techniques
The diagnosis and management of clinically relevant bone 
fractures are based on a clinical examination indicating pain 
localized to the level of the fracture along with confirmatory 
imaging studies (71). Cementoplasty refers to a technique where 
cement is delivered percutaneously to the spinal bones or other 
weight-bearing bones for stability purposes. It broadly includes 
procedures like vertebroplasty, kyphoplasty, sacroplasty, and 
osteoplasty (72).
Vertebroplasty and Kyphoplasty
Untreated vertebral compression fractures can result in a spinal 
cord compression with irreversible neurological symptoms 
and paraplegia (73, 74). Pain severity or the medications used 
to control pain can cause considerable functional impairment, 
significantly limiting patients’ mobility and ability to carry out 
day-to-day activities (75).
Vertebral augmentation techniques—vertebroplasty or 
kyphoplasty—are often done at an outpatient setting, at which 
image-guided injection of bone cement (methyl methacrylate) 
is injected into a collapsed vertebral body. This approach may be 
valuable for patients when pain is unresponsive to conservative 
treatments and no other options like RT are available, and for 
patients whose pain causes poor functional status thus limiting 
their life expectancy. Compared to non-surgical management, 
kyphoplasty was found to be an effective and safe treatment 
that rapidly reduced pain and improved function. A recently 
published systematic review including 111 clinical reports with 
4,235 patients evaluated vertebral augmentation (vertebroplasty 
or kyphoplasty) for cancer-related vertebral compression frac-
tures. Researchers found these two procedures to significantly 
and rapidly reduced pain intensity as well as significantly 
decrease the need for opioid pain medication, and functional 
disabilities related to back and neck pain (76). Beyond the con-
traindications mentioned above for invasive procedures, addi-
tional contraindications for these procedures include epidural 
disease, a fracture with new neurological impairment attributed 
to it, and fractured vertebra with a burst element penetrating the 
spinal canal (77).
Osteoplasty
It is the percutaneous injection of bone cement into painful bone 
metastases at extraspinal regions. Two retrospective studies, 
comprising a total of 76 patients, evaluated osteoplasty under 
CT or fluoroscopy found this technique effective and valuable 
as a method for reduction of pain and improvement of patients’ 
quality of life (78, 79). In particular, for patients with lung cancer 
metastatic to the bones, a large retrospective series demonstrated 
vertebroplasty and cementoplasty to be effective and safe as a 
means to decrease pain and enhance mobility in patients with 
vertebral and extra spinal metastases (80).
RF Ablation and Cryoablation of Painful Bone 
Metastases
Several new ablation treatment strategies have been reported to 
be effective over the last two decades. These treatments consist of 
image-guided (CT, fluoroscopy) destruction of soft tissues or bone 
tumors (either primary or metastatic). Among these techniques, 
RF ablation is the most studied and frequently used modality, but 
cryoablation, laser ablation, and microwave ablation have all been 
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also reported. The pain treated with these techniques should be 
limited to one or two sites, and patients with numerous painful 
tumors should be treated systemically. Ablative therapy tends 
to be most effective in soft-tissue tumors and bone tumors with 
dominant osteolytic component.
RF Ablation
High-frequency, alternating current is passed to an adjacent 
tissue via a needle electrode and results in heating of the tissue, 
denaturation of proteins, and cell death. It is usually performed 
with local anesthesia or under moderate sedation. Careful con-
sideration of the regional anatomy should be carefully assessed 
and considered. As anatomy is frequently disturbed in these 
patients, the ablation zone should not be extended to less than 
1 cm of critical structures such as the bowel, urinary bladder, or 
spine (81). Two multicenter clinical trials conducted on a large set 
of patients with a wide range of solid malignancies (the majority 
were lung, colon, and renal metastases) confirmed that RF abla-
tion as a means to decrease pain due to bone metastatic disease is 
safe and well tolerated by patients (82, 83).
Percutaneous Cryoablation
This method uses room temperature-pressurized argon and 
helium gasses for tissue freezing and warming, respectively. The 
cryoprobes are placed into the tumor using CT/fluoroscopy for 
tumors within bones or deep in the pelvis. The passage of gas 
through the probe results in rapid cooling that reaches −100°C 
within a few seconds, forming a low-attenuation ice ball that is 
readily visible with the CT imaging (or MRI). Tissue destruction 
is complete at −20 to −40°C, approximately 3- to 5-mm deep to 
the visible edge of the ice ball. A synchronous use of multiple 
cryoprobes can be done to allow for a complete coverage of 
the tumor and its immediate surroundings. The method is less 
studied than RFA, but case series and reports have established 
its efficacy. Its main advantage over RF is its ability to be readily 
visualized intra-procedurally with intermittent non-enhanced 
CT or MR imaging (84).
iNTeGRATiNG iNTeRveNTiONAL PAiN 
TReATMeNT iNTO AN ONCOLOGY 
PRACTiCe
Multidisciplinary symptom management results in positive out-
comes described in terms of significant relief of cancer pain and 
other cancer-related symptoms like fatigue, depression, anxiety, 
and drowsiness. It also impacts positively on patients’ disability 
and eventually on opioid reduction (85).
Traditionally, interventional treatments have been regarded 
as a last resort to relieving cancer pain in those patients where 
conventional drug therapies have failed. The term “fourth step 
of the WHO ladder” was coined with views of placing inter-
ventional cancer pain within the well-known WHO three steps 
clinical algorithm (86). Major efforts are being conducted to 
prove that interventional pain management indicated at early 
stages of the disease or before the pain becomes unmanageable 
with drugs may be a better option. Potential benefits of early 
blocks include better health status and enhanced performance 
to face the disease and its treatment and avoiding or delaying 
opioid escalation to manage pain. Rather than a fourth step of 
the ladder, interventional cancer pain approaches should be 
regarded as a handrail accompanying all the three steps of the 
WHO ladder.
Interaction between different clinical specialties may be 
challenging if their mutual approaches are poorly understood or 
perceived ineffective and/or dangerous. In the case of interven-
tional cancer pain management, this is more challenging since the 
outcomes can seldom be presented in terms of evidence-based 
medicine.
Oncologist must identify those patients whose pain is 
inadequately controlled and ask themselves if an interventional 
approach may be indicated. With progressive learning, the indi-
cations and contraindications become clearer, and the cases are 
referred in a timelier and more appropriate fashion. Interventional 
pain clinicians must identify, in turn, the potential implications of 
their techniques on the patient’s status like, for example, the risk 
of bleeding when anticoagulated or receiving chemotherapy, the 
anatomical alterations a tumor may cause when attempting to tar-
get a specific nerve structure, or the changes in analgesic therapy 
necessary to apply after a successful nerve block or neurolysis. A 
fluid and bidirectional communication is key to integrate success-
ful analgesic strategies into the oncology care.
SUMMARY
Interventional cancer pain approaches can provide valuable help 
to treating oncologist in cases of lung cancer with pain that is not 
satisfactorily relieved with conventional medical management. 
The indications and contraindications, the goals of treatment, 
the limitation of the technique, and the post-procedure care are 
necessary elements to be discussed between clinicians involved 
and the patient and their caregivers. Because the available scien-
tific evidences are sparse, at present, interventional cancer pain 
remains an optional alternative rather than a natural indication. 
Only those teams integrating a specialist in interventional cancer 
pain may offer these options to selected cases presenting with 
challenging cancer pain syndromes.
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